Latest Research And Development News

Neurotech International reports encouraging Phase I human pharmacokinetic results for its pediatric cannabinoid drug NTI164, alongside published clinical trial data in Rett Syndrome and key regulatory progress in the US and Australia.

One Click Group Limited reported a 28% revenue increase to $1.3 million in H1 2025, launched a new $500 cash advance product, and surpassed 200,000 registered users, setting the stage for further growth.

Golden Mile Resources has completed its first Reverse Circulation drilling campaign at the Pearl Copper Project in Arizona, revealing significant copper, lead, zinc, and silver mineralisation. Meanwhile, drilling continues at its Leonora Gold JV with assay results pending.

Amplia Therapeutics reports encouraging ACCENT trial results for its FAK inhibitor narmafotinib, including rare complete responses in pancreatic cancer, alongside a $27.5 million capital raise to fund ongoing clinical development.

Fluence Corporation reported a robust 64.7% revenue increase in the first half of 2025, driven by strong project execution in Ivory Coast and growth in key business units. Despite tariff uncertainties and a cautious China outlook, the company maintains its full-year guidance and eyes further backlog expansion.

Silver Mines Limited progresses regulatory approvals for its flagship Bowdens Silver Project in NSW while acquiring promising US assets, enhancing its exploration pipeline with minimal upfront costs.

INOVIQ Limited reports breakthrough results for its ovarian cancer screening test achieving perfect early-stage detection, alongside promising advances in its CAR-exosome cancer therapy program.

Fluence Corporation Limited reported a positive net operating cash flow of US$5.1 million for Q2 2025, boosting its cash reserves to US$12.7 million and maintaining solid liquidity through revolving credit and loan facilities.

Aruma Resources has confirmed maiden drilling plans at its Fiery Creek Copper Project in Queensland and secured $900,000 in a recent placement to accelerate exploration across its portfolio.

Strategic Elements Ltd has marked significant progress in its Energy Ink™ prototype trials and underground mining technology, maintaining a robust financial footing with $4.21 million cash and no debt.

PainChek Limited has secured a A$7.5 million placement to fuel its international expansion, with US FDA clearance for its adult pain assessment app expected imminently. The company reports strong license growth and a 26% revenue increase year-on-year.

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.